Riociguat Bayer

DRUG4 trials

Sponsors

Bayer AG, Thoraxklinik Heidelberg gGmbH

Conditions

Chronic Thromboembolic Pulmonary HypertensionPatients symptomatic with pulmonary hypertension associated with left ventricular systolic dysfunction (PH-sLVD)Pulmonary Arterial HypertensionPulmonary arterial hypertension (PAH)Pulmonary vascular disease

Phase 2

(14308) Randomized, double-blind, placebo-controlled, parallel-group, multi-center study to evaluate the hemodynamic effects of Riociguat (BAY 63-2521) as well as safety and kinetics in patients with pulmonary hypertension associated with left ventricular systolic dysfunction.

CompletedCTIS2023-507001-34-00

Bayer AGPatients symptomatic with pulmonary hypertension associated with left ventricular systolic dysfunction (PH-sLVD)

Start: 2010-04-29End: 2025-07-23Target: 68Updated: 2025-04-29

Efficacy and safety of riociguat (MK-4836) in incipient pulmonary vascular disease as an indicator for early pulmonary arterial hypertension Double-blind, randomized, multicenter, multinational, placebo-controlled phase IIa study

CompletedCTIS2023-509695-42-00

Thoraxklinik Heidelberg gGmbHPulmonary vascular disease

Start: 2022-07-25End: 2025-07-31Target: 43Updated: 2025-04-30

Phase 3

(15681) Open-label, individual dose titration study to evaluate safety, tolerability and pharmacokinetics of riociguat in children from 6 to less than 18 years of age with pulmonary arterial hypertension (PAH)

Active, not recruitingCTIS2023-503536-40-00

Bayer AGPulmonary arterial hypertension (PAH)

Start: 2016-02-23Target: 12Updated: 2025-10-07

Phase 4

An open-label, prospective, single centre study of the effects of Riociguat on RIght VEntricular size and function in Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension

CompletedCTIS2023-509696-17-00

Thoraxklinik Heidelberg gGmbHChronic Thromboembolic Pulmonary Hypertension, Pulmonary Arterial Hypertension

Start: 2021-11-05End: 2025-08-13Target: 30Updated: 2025-04-03